Calcineurin inhibitor sparing immunosuppressive regimens in kidney allograft recipients

Polskie Archiwum Medycyny Wewnetrznej

Volumn 119, Issue 5, 2009, Pages 318-325

  Ba̧czkowska, Teresa ^a   Durlik, Magdalena ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Calcineurin inhibitors; CNI sparing; Immune suppression; Kidney transplantation; Nephrotoxicity

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; BELATACEPT; CALCINEURIN INHIBITOR; CYCLOSPORIN A; DACLIZUMAB; EVEROLIMUS; GLUCOCORTICOID; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; SPIRONOLACTONE; TACROLIMUS;

BONE TURNOVER; CARDIOTOXICITY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GRAFT RECIPIENT; GRAFT SURVIVAL; HEADACHE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INSOMNIA; KIDNEY ALLOGRAFT; KIDNEY ALLOGRAFT REJECTION; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY INJURY; LIMB TREMOR; NEPHROTOXICITY; NEUROTOXICITY; OSTEOPOROSIS; PROTEINURIA; REVIEW; SIDE EFFECT;

EID: 67649306967     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.684     Document Type: Review

References (55)

1. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: Have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant. 2004; 4:1289-1295.
2. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant. 2004; 4: 378-383.
3. Gurk-Turner C, Airee R, Philosophe B, et al. Thymoglobulin dose optimisation for induction therapy in high risk kidney transplant recipients. Transplantation. 2008; 85:1425-1430.
4. Navarro AP, Sohrabi S, Reddy M, et al. Dual transplantation of marginal kidneys from nonheart beating donors selected using machine perfusion viability criteria. J Urol. 2008; 179: 2305-2309.
5. Saas R Courivaud C, Bamoulid J, et al. Immune monitoring of kidney transplant recipients: can markers predictive of over immunosuppression be identified? Ann Pharm Fr. 2008; 66:115-121.
6. Nankivell BJ, Borrows RJ, Fung CL, et al. Calcineurin inhibitor nephrotoxicity: Longitudinal assessment by protocol histology. Transplantation. 2004; 78: 557-565.
7. Pretagostini R, Cinti P, Lai Q, et al. Minimization of immunosuppressive therapy and immunological monitoring of kidney transplant recipients with long-term allograft survival. Transpl Immunol. 2008; 20: 3-5.
8. Fellsrom B. Cyclosporine nephrotoxicity. Transplant Proc. 2004; 36 (Suppl 2S): S220-S223.
9. Keogh A. Calcineurin inhibitors in heart transplantation. J Heart Lung Transplant. 2004; 23 (Suppl 5): S202-S206.
10. Mihatsh MJ, Gudat F, Ryffel B, et al. Cyclosporine nephropathy. In: Tischer CC, Brenner BM, eds. Renal pathology with clinical and functional correlations. Philadelphia. JB Lippincott Co, 1994: 1641-1681.
11. Kambham N, Nagarajan S, Shah S, et al. A novel, semiquantitative, clinically correlated calcineurin inhibitor toxicity score for renal allograft biopsies. Clin J Am Soc Nephrol. 2007; 2:135-142.
12. Friedlander M Fibrosis and diseases of the eye. J Clin Invest. 2007; 117:576-586.
13. Khanna A, Plummer M, Bromberek C, et al. Expression of TGF-beta and fibrogenic genes in renal transplant recipients with tacrolimus and cyclosporine nephrotoxicity. Kidney Int. 2002; 62: 2257-2263.
14. Campistol JM, Inigo R Larios S, et al. Role of transforming growth factor-beta 1 in the progression of chronic allograft nephropathy. Nephrol Dial Transplant. 2001; 16 (Suppl 1): 114-116.
15. Perez-Rojas J, Blanco JA, Cruz C, et al. Mineralocorticoid receptor blockade confers renoprotection in pre-existing chronic cyclosporine nephrotoxicity. Am J Physiol Renal Physiol. 2007; 292: F131-F139.
16. Sharma R, Khanna A, Sharma M, Savin JS. Transforming growth factor B1 increases albumin permeability of isolated rat glomeruli via hydroxyl radicals. Kidney Int. 2000; 58:131-136.
17. Han SY, Mun KC, Choi HJ, et al. Effects of cyclosporine and tacrolimus on the oxidative stress in cultured mesangial cells. Transplant Proc. 2006; 38: 2240-2241.
18. Liu Youhua. Renal fibrosis: new insight into the pathogenesis and therapeutics. Kidney Int. 2006; 69: 213-217.
19. Slattery C, Campbell E, McMorrow T, Ryan MP. Cyclosporine A-induced renal fibrosis. Am J Pathology. 2005; 167: 395-407.
20. Haberal M, Karakayali H, Emiroglu R, et al. Malignant tumours after renal transplantation. Artif Organs. 2002; 26: 778-781.
21. Meneghin A, Hogaboam CM. Infectious disease, the innate immune response, and fibrosis. J Clin Invest. 2007; 117: 530-538.
22. Lo A. Immunosuppression and metabolic syndrome in renal transplant recipients. Metab Syndr Relat Disord. 2004; 2: 263-273.
23. Bozkaya G, Nart A, Uslu A, et al. Impact of calcineurin inhibitors on bone metabolism in primary kidney transplant recipients. Transplant Proc. 2008; 40:151-55.
24. Magnasco A, Rossi A, Catarsi P, et al. Cyclosporin and organ specific toxicity: clinical aspects, pharmacogenetics and prospectives. Curr Clin Pharmacol. 2008; 3:166-173.
25. Kasiske BL, Heim-Duthoy K, Ma JZ. Elective cyclosporine withrawal after renal transplantation. A meta-analysis. JAMA. 1993; 269: 395-400.
26. Gallagher MP, Hall B, Craig J, et al. A randomized controlled trial of cyclosporine withdrawal in renal-transplant recipients: 15-years results. Transplantation. 2004; 15:1653-1660.
27. Heim-Duthoy KL, Chitwood KK, Tortorice KL, et al. Elective cyclosporine withdrawal 1 year after renal transplantation. Am J Kidney Dis. 1994; 24: 846-853.
28. Joss N, Rodger RS, McMillan MA, Junor BJ. Randomized study comparing cyclosporine with azathioprine one year after renal transplantation - 15-year outcome data. Transplantation. 2007; 15: 582-587.
29. Vincenti F, Ramos E, Brattstrom C, et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation. 2001; 71: 1282-1287.
30. Trail HT, Muralidhar K, Acharaya MK, et al. Avoidance of cyclosporine in renal transplantation: effects of daclizumab, mycophenolate mofetil, and steroids. J Am Soc Nephrol. 2000; 11:1933-1936.
31. Hazzan M, Buob D, Labalette M, et al. Assessment of the risk of chronic allograft dysfunction after renal transplantation in a randomized cyclosporine withdrawal trial. Transplantation. 2006; 82: 657-662.
32. Abramowicz D, Del Carmen RM, Vitko S, et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study. J Am Soc Nephrol. 2005; 16: 2234-2240.
33. Smak Gregoor PJ, van Gelder T, Van Besouw NM, van der Mast BJ, et al. Randomized study on the conversion of treatment with cyclosporine to azathioprine or mycophenolate mofetil followed by dose reduction. Transplantation. 2000; 7:143-148.
34. Suwelack B, Gerhardt U, Hohage H. Withdrawal of cyclosporine or tacrolimus after addition of mycophenoalte mofetil in patients with chronic allograft nephropathy. Am J Transplant. 2004; 4: 655-662.
35. Ekberg H, Grinyo J, Nashan B, et al. Cyclosporine sparing with mycophenoalte mofetil, daklizumab and corticosteroids in renal allograft recipients: the CAESAR Study. Am J Transplant. 2007; 7: 560-570.
36. Frimat L, Cassuto-Viguier E, Charpentier B, et al. Impact of cyclosporine reduction with MMF: a randomized trial in chronic allograft dysfunction. The 'reference' study. Am J Transplant. 2006; 6: 2725-2734.
37. Pascual M, Curtis J, Delmonico FL, et al. A prospective, randomized clinical trial of cyclosporine reduction in stable patients greater than 12 months after renal transplantation. Transplantation. 2003; 75:1501-1505.
38. Garcia R, Pinheiro-Machado PG, Felipe CR, et al. Conversion from azathioprine to mycophenolate mofetil followed by calcineurin inhibitor minimization or elimination in patients with chronic allograft dysfunction. Transplant Proc. 2006; 38: 2872-2878.
39. Halloran PR Sirolimus and cyclosporin for renal transplantation. Lancet. 2000; 356:179-180.
40. Srinivas TR, Schold JD, Guerra G, et al. Mycophenolate mofetil/sirolimus compared to other common immunosuppressive regimens in kidney transplantation. Am J Transplant 2007; 7:586-594.
41. Oberbauer R, Segolini G, Campistol JM, et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpant Int. 2005; 18: 22-28.
42. Gonwa TA, Hricik DE, Brinker K, et al. Sirolimus renal function Study Group, Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Transplantation. 2002; 74: 1560-1567.
43. Sampaio EL, Pinheiro-Machado PG, Garcia R, et al. Mycophenolate mofetil vs sirolimus in kidney transplant recipients receiving tacrolimus based immunosuppressive regimen. Clin Transplant. 2008; 22:141-149.
44. Diekmann F, Budde K, Oppenheimer F, et al. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant. 2004; 4:1869-1875.
45. Ciancio G, Burke GW, Gaynor JJ, et al. The use of Campath-1 H as induction therapy in renal transplantation: preliminary results. Transplantation. 2004; 78: 426-433.
46. Pearson TC, Mulgaonkar S, Patel A, et al. Efficacy and safety of mycophenolate mofetil (MMF/sirolimus maintenance therapy after calcineurin inhibitor (CNI| withdrawal in renal transplant recipients: final results of the Spare-The-Nephron (STNI Trial. Am J Transplant. 2008; 8 (Suppl 2): 129.
47. Lebranchu Y, Theirry A, Toupance 0, et al. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. Am J Transplant. 2009; 9:1115-1123.
48. Flechner SM, Goldfarb D, Solez K, et al. Kidney transplantation with si rolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Transplantation. 2007; 83: 883-892.
49. Nashan B, Curtis J, Ponticelli C, et al. Everolimus and reduced-expo sure in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study. Transplantation. 2004; 78: 1332-1340.
50. Srinivas TR, Schold JD, Guerra G, et al. Mycophenolate mofetil/sirolimus compared to other common immunosuppressive regimens in kidney transplantation. Am J Transplant. 2007; 3: 424-425.
51. Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med. 2005; 353:770-781.
52. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Eng J Med. 2007; 357: 2562-2575.
53. Lee S, Coco M, Greenstein SM, et al. The effect of sirolimus on sex hormone levels of male renal transplant recipients. Clin Transplant. 2005; 19:162-167.
54. Fiechner SM, Kobashigawa J, Klintmalm G. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin Transplant. 2008; 22:1-15.
55. Guerra G, Srinivas TR, Meier-Kriesche HU. Calcineurin inhibitor free immunosuppression in kidney transplantation. Transpl Int. 2007; 20: 813-827.